NeuroMetrix, Inc. Reports Total Revenues of $11.3 Million for the Third Quarter of 2007, a Decrease of 26% from the Third Quarter of 2006; Net Loss of $3.6 Million Incurred in the Third Quarter of 2007

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the design, development and sale of proprietary products used to help physicians diagnose neuropathies and neurovascular diseases, announced today the financial results for the three month and nine month periods ended September 30, 2007.